UroGen Pharma to Report Second Quarter 2022 Financial Results on Thursday, August 11, 2022

Rhea-AI Summary

UroGen Pharma Ltd. (Nasdaq: URGN) will announce its Q2 2022 financial results on August 11, 2022, before the market opens. A live audio webcast for the earnings conference call will be held at 10:00 AM ET. UroGen focuses on developing innovative solutions for urothelial and specialty cancers, including its proprietary RTGel™ hydrogel technology and treatments like Jelmyto® and UGN-102. Stakeholders can access the webcast through UroGen's Investor Relations website.

Conference Call and Webcast Scheduled for Thursday, August 11, 2022 at 10:00 AM ET

PRINCETON, N.J.--(BUSINESS WIRE)-- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it will report second quarter 2022 financial results on Thursday, August 11, 2022, prior to the open of the market. The announcement will be followed by a live audio webcast and conference call at 10:00 AM Eastern Time.

A live public webcast of the earnings conference call can be accessed on UroGen’s Investor Relations website. Following the live webcast, a replay will be available on the site for approximately 30 days.

About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. Jelmyto® (mitomycin) for pyelocaliceal solution and investigational treatment UGN-102 (mitomycin) for intravesical solution are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, NJ with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, @UroGenPharma.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220727005288/en/

INVESTORS:

Vincent Perrone

vincent.perrone@urogen.com

609-460-3588 ext. 1093



MEDIA:

Cindy Romano

Director, Corporate Communications

cindy.romano@urogen.com

609-460-3583 ext. 1083

Source: UroGen Pharma Ltd.

FAQ

When will UroGen Pharma report its Q2 2022 financial results?

UroGen Pharma will report its Q2 2022 financial results on August 11, 2022.

What time is UroGen Pharma's Q2 2022 earnings conference call?

The earnings conference call is scheduled for 10:00 AM ET on August 11, 2022.

Where can I access UroGen Pharma's earnings webcast?

You can access the earnings webcast on UroGen's Investor Relations website.

What is UroGen Pharma known for?

UroGen Pharma is known for developing innovative treatments for urothelial and specialty cancers, including its RTGel™ technology.